LEADER 02941oam 2200457 450 001 9910136407603321 005 20230621135800.0 010 $a9782889193325 (ebook) 035 $a(CKB)3710000000612036 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/45512 035 $a(EXLCZ)993710000000612036 100 $a20191103c2014uuuu uu | 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDrug-diagnostics co-development in oncology$b[electronic resource] /$ftopic editor Jan Trøst Jørgensen 210 $cFrontiers Media SA$d2014 210 1$aFrance :$cFrontiers Media SA,$d2014 215 $a1 online resource (111 pages) $ccolour illustrations, charts 225 1 $aFrontiers Research Topics 320 $aIncludes bibliographical references. 330 $aThe idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970?s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest?, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs. 606 $aOncology 610 $aIHC 610 $afish 610 $aprecision medicine 610 $aNGS 610 $aDrug-diagnostic co-development 610 $acompanion diagnostics 610 $aoncology 610 $apersonalized medicine 615 0$aOncology. 676 $a615.1/9 700 $aJan Trost Jorgensen$4auth$01367185 702 $aJørgensen$b Jan Trøst 801 0$bUkMaJRU 912 $a9910136407603321 996 $aDrug-diagnostics co-development in oncology$93389914 997 $aUNINA LEADER 01161nam--2200385---4500 001 990000535360203316 005 20051115175428.0 035 $a0053536 035 $aUSA010053536 035 $a(ALEPH)000053536USA01 035 $a0053536 100 $a20010702d1994----km-y0ENGy0103----ba 101 $aita$aeng 102 $aIT 200 1 $aCostiera amalfitana$dThe Amalfi coast$fAnthony Coronia$gtesti di Gore Vidal e Muir Weissinger$g 210 $aNapoli$cPironti$d1994 215 $a1 v.$cill.$d23 cm 410 $12001 676 $a779.364574 700 1$aCORONIA,$bAnthony$0546196 702 1$aVIDAL,$bGore 702 1$aWEISSINGER,$bMuir 702 1$aPICONE,$bLetizia 801 0$aIT$bsalbc$gISBD 912 $a990000535360203316 951 $aXV.1.A. 355(V G 304)$b128056 LM$cV G 959 $aBK 969 $aLOCALE 979 $aPATTY$b90$c20010702$lUSA01$h1126 979 $aPATTY$b90$c20011030$lUSA01$h1303 979 $c20020403$lUSA01$h1702 979 $aPATRY$b90$c20040406$lUSA01$h1637 979 $aCOPAT1$b90$c20051115$lUSA01$h1754 996 $aCostiera amalfitana$9885643 997 $aUNISA